Newgenivf cleared XRP and held approximately 13,000 SOL units; lost nearly US$1.28 million

NewGenIvf completed its XRP clearance and held approximately 13,000 SOLs at the end of the year, with a book loss of nearly US$1.28 million.

According to Amendment No. 2 to the SEC Form F-1 filed by NewGenIvf Group Limited (NASDAQ: NIVF) on September 10, 2026, the Cayman Islands-based in vitro fertilization (IVF) service provider disclosed its digital asset disposal in 2025. The company completed the liquidation operation of XRP, held approximately 13,000 SOLs at the end of the year, and recorded an unrealized valuation loss of approximately US$1.28 million. The disclosure defines NewGenIvf's XRP exit as part of its corporate treasury management plan, which is completely independent of its core fertility business.

This disclosure is particularly eye-catching as more and more listed companies allocate idle cash to digital assets. However, what is unique about NewGenIvf's case lies in its reverse performance: the company actively traded four tokens in 2025, but held only one Solana asset at the end of the year. This concentration of positions causes an otherwise profitable trading year to turn into a net crypto asset loss on the books.

Specific details of the XRP clearance confirm

According to Note No. 8 on Form F-1/A, NewGenIvf purchased and sold the equivalent of 146,432.14 XRPs during the year ended December 31, 2025, and the XRP balance at the end of the year was zero. The round-trip transaction generated realized gains of $10,849, meaning NewGenIvf's XRP liquidation ended in a profit rather than a loss.

The filing document did not disclose the specific date, price, trading venue or counterparty of the XRP purchase and sale, nor did it state whether the funds from the sale were redeployed to other tokens. Because these transaction-level details are not included in the summary activity table, any inference that XRP sales revenue was used to purchase Solana lacks documented support.

XRP is just one of four types of tokens that NewGenIvf will circulate in 2025. The company bought and sold 8.77 BTC and 8.95 ETH during the year, recording realized gains of US$12,569 and US$223 respectively. All BTC, ETH and XRP positions will be fully liquidated by December 31. Although XRP was trading at close to $1.37 as of September 13, 2026, this has nothing to do with the company's achieved results in 2025. At the same time, Ripple's own commercial footprint continues to expand, penetrating into Brazil's payments sector and pursuing VASP licenses, which has nothing to do with NewGenIvf's passive trading behavior.

Reported SOL positions and limits

According to the same document, as of December 31, 2025, NewGenIvf held 13,000.23 SOLs, which was the only remaining crypto asset on its balance sheet at the end of the previous year. The activity table shows that in 2025, the company purchased 46,118.55 SOL units and sold 33,118.32 SOL units. The net result is the year-end open positions in the report.

The SOL cost base held at year-end was US$2,906,222 and the fair value was US$1,630,827. As of that date, the assets were not subject to any contractual sales restrictions, pledges or lock-in arrangements, the document states.

• NewGenIvf's SOL position on December 31, 2025: 13,000.23 SOL
• Year-end SOL cost basis: US$2,906,222
• Year-end SOL fair value: US$1,630,827

It should be noted that the data of 13,000.23 SOLs are only year-end snapshots and not current positions. The document only establishes positions as of December 31, 2025 and does not provide updates during the September 2026 disclosure window. Therefore, this balance should not be regarded as a real-time treasury for the company, nor should it be multiplied by current SOL prices to estimate the present value. As of September 13, 2026, Solana's trading price was approximately US$102.10 and its market value was close to US$59.9 billion, but this background information does not confirm whether NewGenIvf still holds these tokens.

The actual composition of a loss of US$1.28 million

The loss of approximately US$1.28 million mentioned in the headline refers to a single project: 2025 SOL's unrealized valuation loss of US$1,275,395, which is the difference between the cost of US$2,906,222 of the token and the year-end fair value of US$1,630,827. This was a mark-to-market book loss, not a realized cash loss, and was not related to XRP's liquidation.

The key is net calculation. The total realized crypto revenue for the four types of tokens reached US$942,915. As a result, after applying SOL's impairment, the company recorded a net crypto loss of $332,480 in net other income (expenses). In Solana alone, realized gains of $919,720 were offset by valuation losses, resulting in a net loss for Solana of $355,675 for the year.

Accounting treatment determines visual presentation. NewGenIvf adopts the ASC 350-60 standard, uses active market prices quoted by ASC 820, and remeasures crypto assets at fair value in each period, with changes included in net income. This treatment causes the year-end decline in any unsold tokens to be reflected directly on the income statement. This is why losses are still reported in a trading year with nearly $943,000 in realized gains, and this dynamic also shapes how corporate treasuries accumulated by large Ethereum such as Bitmine will appear in future documents.

Disclosure details that still need to be verified

The company stated that its core business is still IVF services, that encryption activities are not core operations, and that it does not engage in mining, pledge, borrowing or other income-generating encryption activities. The document is a registration document, not an SEC enforcement action or endorsement, and its balance data is only valid as of December 31, 2025.

Key issues that remain unresolved in public records include whether NewGenIvf still holds 13,000.23 SOL units after the end of the year, the execution date and price behind XRP round-trip transactions, and any transactions after 2025. Although there was an unconfirmed report that the company still held an exact SOL balance as of the study date, the claim was unverified and the document itself only supported year-end data. Corporate encryption strategies can quickly reverse, as Bitcoin Suisse laid off workers when conditions change, underscoring why nine-month-old snapshots should not be treated as real-time data.

Frequently Asked Questions (FAQ)

Has NewGenIvf quit XRP?

Yes. The document shows that it bought and sold 146,432.14 XRPs in 2025, and the XRP balance at the end of the year was zero, and this position achieved a gain of US$10,849.

How much SOL does NewGenIvf report hold?

As of December 31, 2025, there are approximately 13,000 SOLs (specifically 13,000.23). The documents did not confirm whether the balance was still valid, and Solana's broader ecosystem activities (such as the launch of tokenized stocks such as FLWS in Solana) were not related to the company's positions.

Is the loss caused by XRP clearing?

No. The approximately $1.28 million loss was an unrealized write-down on Solana's valuation; the XRP transaction was profitable and the company's overall net crypto loss in 2025, after deducting realized gains, was $332,480.

What should readers focus on next?

The specific trigger point is NewGenIvf's next SEC filing, which will reveal any changes in SOL positions after the end of the year and whether continued fair value remeasurement under the ASC 350-60 guideline will reverse the crypto sector back into profitability or deepen losses.

Disclaimer : This article is for reference only and does not constitute financial or investment advice. There are significant risks in the cryptocurrency and digital asset markets. Be sure to conduct independent research before making a decision.